Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (2160)	2/2/2000 8:33:00 AM
From: DanZ	Read Replies (1) \| Respond to of 5582

Reuters Health wrote the article that you are quoting from. It isn't a press release written by Gum Tech, Gel Tech, or anyone affiliated with the company. The number of patients isn't known precisely, yet you drew a conclusion about whether it is statistically significant. LMAO. The main importance of this study, from my perspective, is that Gum Tech can now claim that Zicam is clinically proven to reduce the duration and severity of the common cold by 78%. It doesn't matter if the study is ever published (although I hope it is). It doesn't matter if you think it is statistically significant. All your whining, and Wexler's ludicrous fraud BS, won't stop Gum Tech from claiming that Zicam is clinically proven to reduce the duration and severity of the common cold by 78% in their advertising. Zicam is already selling well, and it's going to sell even better now that they can make this claim. While you are jumping up and down complaining, Gum Tech will be claiming, Zicam will be selling, and GUMM will be rising. As one of your other short cohorts likes to say: Have fun! Dan

To: Hank who wrote (2160)	2/2/2000 9:49:00 AM
From: Mike M	Read Replies (2) \| Respond to of 5582

Hank, don't lose perspective on this. This isn't cancer research. People will decide for themselves whether this product has application in their lives. In the mean time it isn't a good candidate for a short sell unless you are absolutely convinced that their Zicam, joint venture and dental gum businesses are all going to fall flat on their face. Risky bet particularly since they just passed one of your milestones. They are now profitable. I have been in your shoes before, denying, against the evidence, that someone could execute their business plan. It wasn't a good experience.